WHO ICTRP trial
NEOVACC: A personalised DNA vaccine for patients with advanced lung cancer
ISRCTN11752949 · International Standard Randomised Controlled Trial Number (ISRCTN) · Recruiting
Key facts
| Trial ID | ISRCTN11752949 |
|---|---|
| Public title | NEOVACC: A personalised DNA vaccine for patients with advanced lung cancer |
| Scientific title | Targeting non-small cell lung cancer with Doggybone personalised cancer DNA vaccines (dbPCV) |
| Primary sponsor | University of Liverpool |
| Registry | International Standard Randomised Controlled Trial Number (ISRCTN) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | Phase I |
| Countries | United Kingdom;England |
| Conditions | Non-small cell lung cancer (NSCLC) with PDL1 expression =50% which does not achieve tumour clearance with anti-PD1 treatment Cancer |
| Interventions | The NEOVACC doggybone personalised cancer vaccines (dbPCV) will be administered by PharmaJet Stratis Needle-free injection system. Participants will receive a 2mg/ml dose of dbPCV in 2 divided doses of 0.5ml every 3 weeks for the first 24… |
| Registration date | Aug 5, 2025 |
| Target size | 15 |
| Secondary IDs | Nil known;Nil known;UoL001847 |
| Registry page | isrctn.com |
At a glance
- Yes Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: